CG Oncology, Inc. Files Amendment No. 2 to S-1 Registration Statement

TL;DR

<b>CG Oncology, Inc. has filed an S-1/A amendment, signaling progress towards a public offering.</b>

AI Summary

CG Oncology, Inc. (CGON) filed a Amended IPO Registration (S-1/A) with the SEC on January 23, 2024. CG Oncology, Inc. filed an S-1/A (Amendment No. 2) on January 23, 2024. The company is incorporated in Delaware and operates in the Biological Products sector. Its principal executive offices are located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618. The filing indicates CG Oncology, Inc. is a non-accelerated filer, smaller reporting company, and emerging growth company. The registration statement is for a proposed sale to the public, with the date of commencement to be determined.

Why It Matters

For investors and stakeholders tracking CG Oncology, Inc., this filing contains several important signals. This amendment indicates the company is moving forward with its plans to become publicly traded, which could provide significant capital for research and development. As an emerging growth company, CG Oncology may utilize extended transition periods for new accounting standards, potentially impacting financial reporting timelines.

Risk Assessment

Risk Level: low — CG Oncology, Inc. shows low risk based on this filing. The filing is an S-1/A amendment, which is a routine step in the IPO process and does not contain new financial performance data or significant business updates that would alter the risk profile.

Analyst Insight

Monitor for the effectiveness of the registration statement and subsequent IPO pricing for potential investment opportunities.

Key Numbers

• 333-276350 — SEC File Number (Registration Statement)
• 2836 — SIC Code (Biological Products)
• 371611499 — IRS Number (Employer Identification)

Key Players & Entities

• CG Oncology, Inc. (company) — Registrant
• Arthur Kuan (person) — Chairman and Chief Executive Officer
• Latham & Watkins LLP (company) — Legal counsel
• Cooley LLP (company) — Legal counsel
• Delaware (jurisdiction) — State of incorporation
• Irvine, CA (location) — Business address

Forward-Looking Statements

• CG Oncology, Inc. will complete its IPO within the next 3 months. (CG Oncology, Inc.) — medium confidence, target: 2024-04-23

FAQ

Industry Context

CG Oncology operates in the biotechnology sector, specifically focusing on biological products for oncology treatments.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

1. Review the full S-1/A filing for detailed business operations and risk factors.
2. Track future SEC filings for updates on the IPO timeline and pricing.
3. Analyze the company's clinical pipeline and market potential upon further disclosure.

Key Dates

• 2024-01-23: Filing Date — Amendment No. 2 to Form S-1 Registration Statement filed.

Year-Over-Year Comparison

This is an amendment to a previously filed registration statement, indicating ongoing progress in the IPO process.

Key Financial Figures

• $16.00 — l public offering price will be between $16.00 and $18.00 per share. We have applied t
• $18.00 — fering price will be between $16.00 and $18.00 per share. We have applied to list our
• $9.9 billion — t has been forecast to be approximately $9.9 billion by 2028, according to Evaluate Pharma.

Filing Documents

• d551455ds1a.htm (S-1/A) — 2263KB
• d551455dex51.htm (EX-5.1) — 11KB
• d551455dex231.htm (EX-23.1) — 2KB
• d551455dexfilingfees.htm (EX-FILING FEES) — 15KB
• g551455g0117130719391.jpg (GRAPHIC) — 2KB
• g551455g0117130719748.jpg (GRAPHIC) — 2KB
• g551455g03p01.jpg (GRAPHIC) — 55KB
• g551455g08o97.jpg (GRAPHIC) — 140KB
• g551455g12m13.jpg (GRAPHIC) — 144KB
• g551455g13p01.jpg (GRAPHIC) — 120KB
• g551455g15m15.jpg (GRAPHIC) — 265KB
• g551455g19a20.jpg (GRAPHIC) — 162KB
• g551455g22a22.jpg (GRAPHIC) — 34KB
• g551455g23a23.jpg (GRAPHIC) — 109KB
• g551455g24a25.jpg (GRAPHIC) — 124KB
• g551455g59q43.jpg (GRAPHIC) — 176KB
• g551455g78c79.jpg (GRAPHIC) — 63KB
• g551455g88j37.jpg (GRAPHIC) — 135KB
• g551455g89m10.jpg (GRAPHIC) — 113KB
• 0001193125-24-012523.txt (&nbsp;) — 4560KB

Risk Factors

Risk Factors 14 Special Note Regarding Forward-Looking Statements 75 Market and Industry Data 76

Use of Proceeds

Use of Proceeds 77 Dividend Policy 79 Capitalization 80

Managements Discussion and Analysis of Financial

Managements Discussion and Analysis of Financial Condition and Results of Operations 85

Business

Business 101 Management 134 Page Executive and Director Compensation 142 Certain Relationships and Related Person Transactions 161 Principal Stockholders 166

Description of Capital Stock

Description of Capital Stock 168 Shares Eligible For Future Sale 174 Material United States Federal Income Tax Consequences to Non-U.S. Holders 177

Underwriting

Underwriting 181 Legal Matters 191 Experts 191 Where You Can Find More Information 191 Index to Financial Statements F-1 Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus, or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus, or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should carefully read this entire prospectus, including the information in the sections title

View Full Filing

View this S-1/A filing on SEC EDGAR